Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Paul Berger

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nature|October 26, 2007
Old laws stop drugs being used in valuable new waysS Paul Berger
Lancet (London, England)|October 22, 2008
Brain science and addictionS Paul Berger
The American Journal of Drug and Alcohol Abuse|December 31, 2004
Fluoxetine attenuates adrenocortical but not subjective responses to cocaine cuesDebra S Harris, Steven L Batki, S Paul Berger
Behavioral Neuroscience|February 28, 2007
Anisomycin disrupts a contextual memory following reactivation in a cocaine-induced locomotor activity paradigmRick E Bernardi, K Matthew Lattal, S Paul Berger
Behavioural Brain Research|June 2, 2009
Modafinil reinstates a cocaine conditioned place preference following extinction in ratsRick E Bernardi, Jason R Lewis, K Matthew Lattal, et al.
Learning & Memory (Cold Spring Harbor, N.Y.)|November 27, 2009
Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala beta2- and alpha1-adrenergic antagonistsRick E Bernardi, Andrey E Ryabinin, S Paul Berger, et al.
Psychopharmacology|March 14, 2009
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismMelanie A Paquette, Katherine Foley, Elizabeth G Brudney, et al.
Neuropharmacology|January 19, 2010
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonismMelanie A Paquette, Akari M Anderson, Jason R Lewis, et al.
Psychopharmacology|February 8, 2013
The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian ratNirmal Bhide, David Lindenbach, Margaret A Surrena, et al.
The European Journal of Neuroscience|August 7, 2012
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsMelanie A Paquette, Alex A Martinez, Teresa Macheda, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nature|October 26, 2007
Old laws stop drugs being used in valuable new waysS Paul Berger
Lancet (London, England)|October 22, 2008
Brain science and addictionS Paul Berger
The American Journal of Drug and Alcohol Abuse|December 31, 2004
Fluoxetine attenuates adrenocortical but not subjective responses to cocaine cuesDebra S Harris, Steven L Batki, S Paul Berger
Behavioral Neuroscience|February 28, 2007
Anisomycin disrupts a contextual memory following reactivation in a cocaine-induced locomotor activity paradigmRick E Bernardi, K Matthew Lattal, S Paul Berger
Behavioural Brain Research|June 2, 2009
Modafinil reinstates a cocaine conditioned place preference following extinction in ratsRick E Bernardi, Jason R Lewis, K Matthew Lattal, et al.
Learning & Memory (Cold Spring Harbor, N.Y.)|November 27, 2009
Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala beta2- and alpha1-adrenergic antagonistsRick E Bernardi, Andrey E Ryabinin, S Paul Berger, et al.
Psychopharmacology|March 14, 2009
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismMelanie A Paquette, Katherine Foley, Elizabeth G Brudney, et al.
Neuropharmacology|January 19, 2010
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonismMelanie A Paquette, Akari M Anderson, Jason R Lewis, et al.
Psychopharmacology|February 8, 2013
The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian ratNirmal Bhide, David Lindenbach, Margaret A Surrena, et al.
The European Journal of Neuroscience|August 7, 2012
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsMelanie A Paquette, Alex A Martinez, Teresa Macheda, et al.
Pageof 2